Cancer Research and Treatment

Original Articles
Lung and Thoracic cancer Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer: Miso Kim, Soyeon Kim, Jeemin Yim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo; Cancer Res Treat. 2023;55(4):1134-1143.

Lung and Thoracic cancer Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer: Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo; Cancer Res Treat. 2022;54(1):140-149.

General Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea: Dalyong Kim, Shin Hye Yoo, Seyoung Seo, Hyun Jung Lee, Min Sun Kim, Sung Joon Shin, Chi-Yeon Lim, Do Yeun Kim, Dae Seog Heo, Chae-Man Lim; Cancer Res Treat. 2022;54(1):20-29.

CNS cancer Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae: Joo Ho Lee, Keun-Yong Eom, Ji Hoon Phi, Chul-Kee Park, Seung Ki Kim, Byung-Kyu Cho, Tae Min Kim, Dae Seog Heo, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Seung Hong Choi, Soon Tae Lee, Sung Hye Park, Kyu-Chang Wang, Il Han Kim; Cancer Res Treat. 2021;53(4):983-990.

Palliative medicine Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study: Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo; Cancer Res Treat. 2021;53(2):584-592.

Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients: Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo; Cancer Res Treat. 2020;52(3):917-924.

The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis: Jae Sik Kim, Bhumsuk Keam, Dae Seog Heo, Doo Hee Han, Chae-Seo Rhee, Ji-hoon Kim, Kyeong Cheon Jung, Hong-Gyun Wu; Cancer Res Treat. 2019;51(4):1313-1323.

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer: Su-Jung Kim, Soyeon Kim, Dong-Wan Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yusoo Lee, Jaemoon Koh, Yoon Kyung Jeon, Dae Seog Heo; Cancer Res Treat. 2019;51(3):1231-1240.

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib: Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo; Cancer Res Treat. 2019;51(3):951-962.

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy: Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo; Cancer Res Treat. 2019;51(1):169-177.

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer: Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo; Cancer Res Treat. 2019;51(1):119-127.

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer: Shin Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo; Cancer Res Treat. 2018;50(3):720-728.

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type: Hyun Jee Kim, Chan-Young Ock, Tae Min Kim, Sung Hee Lee, Ju-Yeun Lee, Sun hoi Jung, Yoon Sook Cho, Miso Kim, Bhumsuk Keam, Dong-Wan Kim, Il Han Kim, Dae Seog Heo; Cancer Res Treat. 2018;50(3):670-680.

Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives: Su-Jin Koh, Shinmi Kim, JinShil Kim, Bhumsuk Keam, Dae Seog Heo, Kyung Hee Lee, Bong-Seog Kim, Jee Hyun Kim, Hye Jung Chang, Sun Kyung Baek; Cancer Res Treat. 2018;50(2):614-623.

Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate: Yoojoo Lim, Jee Min Lim, Won Jae Jeong, Kyung-Hun Lee, Bhumsuk Keam, Tae-Yong Kim, Tae Min Kim, Sae-Won Han, Do Youn Oh, Dong-Wan Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Seock-Ah Im; Cancer Res Treat. 2017;49(4):1033-1043.

The Association between End-of-Life Care and the Time Interval between Provision of a Do-Not-Resuscitate Consent and Death in Cancer Patients in Korea: Sun Kyung Baek, Hye Jung Chang, Ja Min Byun, Jae Joon Han, Dae Seog Heo; Cancer Res Treat. 2017;49(2):502-508.

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer: Miso Kim, Bhumsuk Keam, Tae-Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong-Wan Kim, Hwan Jung Yun, Jong Seok Lee, Dae Seog Heo; Cancer Res Treat. 2017;49(2):416-422.

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma: Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo; Cancer Res Treat. 2017;49(1):129-140.

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis: Ryul Kim, Seokyung Hahn, Junghoon Shin, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo; Cancer Res Treat. 2016;48(3):907-916.

VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma: Seongyeol Park, Soo Jeong Nam, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, J. Hun Hah, Tack-Kyun Kwon, Dong-Wan Kim, Myung-Whun Sung, Dae Seog Heo, Yung-Jue Bang; Cancer Res Treat. 2016;48(2):518-526.

Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era: Hyerim Ha, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo; Cancer Res Treat. 2016;48(1):304-311.

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients: Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2016;48(1):88-97.

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors: Do-Youn Oh, Se-Hoon Lee, Sae-Won Han, Mi-Jung Kim, Tae-Min Kim, Tae-You Kim, Dae Seog Heo, Miyuki Yuasa, Yasuo Yanagihara, Yung-Jue Bang; Cancer Res Treat. 2015;47(4):607-615.

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations: Sehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo; Cancer Res Treat. 2015;47(4):630-637.

Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute: Younak Choi, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo; Cancer Res Treat. 2015;47(4):555-563.

Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer: Yun-Gyoo Lee, Eunyoung Lee, Inho Kim, Keun-Wook Lee, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo; Cancer Res Treat. 2015;47(4):670-675.

The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer: June-Koo Lee, Dong-Wan Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Young-Joo Kim, Dae Seog Heo; Cancer Res Treat. 2015;47(2):182-188.

Cyclophosphamide , Adriamycin and Cisplatin ( CAP ) Combination Chemotherapy for Invasive Thymoma: Young Suk Park, Young Hyuk Im, Won Ki Kang, Chang In Suh, Kee Hyung Lee, Kyung Hae Jung, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1990;22(3):532-539.

Cislatin , Vincristine , Bleomycin and Methotrexate ( PVBM ) Combination Chemotherapy for Advanced Uterine Cervix Cancer: Young Hyuk Im, Kee Hyung Lee, Young Suk Park, Chang In Suh, Won Ki Kang, Hyo Jin Kim, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim, Soon Beom Kang, Hyo Pyo Lee, Jin Yong Lee, Seung Wook; J Korean Cancer Assoc. 1990;22(3):505-518.

Non - Hodgkin's Lymphoma of the Central Nervous System: Chang In Suh, Heung Tae Kim, Young Hyuk Im, Young Suk Park, Won Ki Kang, Dae Seog Heo, Yung Jue Bang, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1990;22(2):323-329.

Antitumor Activity of Lymphokine Activated Killer Cells ( LAK ) and Interleukin-2 Activated Tumor Infiltrating Lymphocytes ( TIL ) to the Cell Lines of Human Renal cell carcinom: Chong Wook Lee, Eun Sik Lee, Dae Seog Heo, Jae Gahb Park; J Korean Cancer Assoc. 1990;22(2):286-298.

Phase 1 Trial of Recombinant Interferon Gamma ( LBD - 001 ) in Cancer Patients: Noe Kyeong Kim, Yung Jue Bang, Dae Seog Heo, Heung Tae Kim, Hyo Jin Kim, Keun Chil Park, Keun Chil Park, Dong Bok Shin, Myung Chul Lee, Byoung Kook Kim, Sang Goo Shin, Seong Hoe Park, Han Ik Cho; J Korean Cancer Assoc. 1990;22(1):86-96.

Establishment of SNU Cell Lines in Growth Factor and Growth hormone Supplemented Medium: Jae Gahb Park, Nam Sook Kwon, Dong Young Noh, In Gyu Hong, Seung Keun Oh, Kuhn Uk Lee, Yong Hyun Park, Sung Kuk Hong, Kuk Jin Choe, Jin Pok Kim, Soo Tae Kim, Dae Seog Heo, Yung Jue Bang, Seon Yang Pa; J Korean Cancer Assoc. 1990;22(1):1-14.

Alternating Chemotherapy with VIP ( VP-16-213 , Ifosfamide , Cis-Platinum ) and CSV ( Cyclophosphamide , Adriamycin , Vincristi: Soon Nam Lee, Dae Seog Heo, Noe Kyeong Kim, Young Soo Shim, Keun Youl Kim, Keun Youl Kim, Charn Il Park; J Korean Cancer Assoc. 1987;19(2):79-87.

Clinical Observation of Acute Transformation in Chronic Myelocytic Leukemia: Dae Seog Heo, Noe Kyeong Kim, In Mok Heu, Mun Ho Lee; J Korean Cancer Assoc. 1982;14(1):31-39.

Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma: Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2014;46(3):261-269.

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo; Cancer Res Treat. 2014;46(4):323-330.

5-fluorouracil and cisplatin(FP) combination chemotherapy in advanced gastric cancer patients treated previously with chemotherapy: Heung Tae Kim, Kyung Hae Jung, Won Ki Kang, Young Suk Park, Chang In Suh, Young Hyunk Im, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1991;23(2):279-290.

5-fluorouracil, epirubicin, cisplatin(FEP) and 5-fluorouracil, cisplatin(FP) combination chemotherapy for advanced pancreatic carcinoma: Ki Hyeong Lee, Won Ki Kang, Chang In Suh, Young Suk Park, Heung Tae Kim, Yoon Koo Kang, Hyo Jin Kim, Dae Seog Heo, Yung Jue Bang, Yong Bum Yoon, Noe Kyeong Kim, Yong Hyun Park; J Korean Cancer Assoc. 1991;23(2):315-322.

Bleomycin, etoposide, cisplatin(BEF) combination chemotherapy for experimental germ cell tumor: Won Ki Kang, Chang In Suh, Young Suk Park, Young Hyuk Im, Heung Tae Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1991;23(2):343-349.

Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, prednisolone(C-MOPP) in Hodgkin's disease: Kyung Hae Jung, Dong Bok Shin, Hyun Ah Kim, Young Iee Park, Tae You Kim, Keun Chil Park, Yoon Koo Kang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1991;23(4):806-813.

Treatment of intermediate-grade non-Hodgkin's lymphoma with CAMP-MOB combination chemotherapy: Chang In Suh, Heung Tae Kim, Dong Bok Shin, Jae Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(1):102-108.

Induction of antileukemic cytotoxicity from peripheral blood lymphocytes of patients with acute myeloid leukemia: Yoon Koo Kang, Dae Seog Heo, Heung Tae Kim, Won Ki Kang, Keun Chil Park, Si Young Kim, Kyung Sam Cho, Sung Rok Kim, Sang Jae Lee, Byoung Kook Kim, Jin Oh Lee, Tae Woong Kang; J Korean Cancer Assoc. 1992;24(2):195-217.

A prospective randomized study of cisplatin versus PEV(cisplatin, etoposide, vinblastine) chemotherapy in advanced non-small cell lung cancer: Ki Hyeong Lee, Won Ki Kang, Joung Soon Jung, Sung Soo Yoon, Young Hyuk Im, Jae Yong Lee, Young Suk Park, Chang In Suh, Dae Seog Heo, Yung Jue Bang, Young Soo Shim, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(2):256-267.

A randomized comparison of antiemetic effect of ondansetron versus MDL(metoclopramide/dexamethasone/lorazepam) in patients receiving cisplatin-based combination chemotherapy: Young Hyuck Im, Young Suk Park, Joungsoon Jang, Jae Yong Lee, Sungsoo Yoon, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(3):378-389.

Palliative chemotherapy of soft tissue sarcoma with adriamycin and dacarbazine(ADIC) and cyclophosphamide, vinblastine, adriamycin and dacarbazine(CYVADIC): Young Suk Park, Won Ki Kang, Chang In Suh, Heung Tae Kim, Hyo Jin Kim, Keun Chil Park, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(3):401-410.

Phase II trial of recombinant interferon-gamma(LBD-001) in patients with malignancies: Chang In Suh, Won Ki Kang, Heung Tae Kim, Jae Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim, Young Suk Park, Keun Chil Park, Sung Rok Kim; J Korean Cancer Assoc. 1992;24(4):549-561.

Combination chemotherapy for the treatment of multiple myeloma: Hyo Jin Kim, Chang In Seo, Keun Chil Park, Heung Tae Kim, Dae Seog Heo, Yung Hue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(4):577-585.

COP-BLAM III(cyclophosphamide/vincristine/prednisolone/bleomycin/ adriamycin/procarbazine) combination chemotherapy for the treatment of intermediate and high grade non-Hodgkin's lymphoma: Keong Hae Jung, Young Iee Park, Kee Heung Lee, Young Suk Park, Chang In Suh, Won Ki Kang, Heung Tae Kim, Cheol Won Suh, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(4):586-595.

The immunological characteristics of tumor infiltrating lymphocytes and tumor draining lymph node lymphocytes in advanced stomach cancer: Jae Yong Lee, Jung Soon Jang, Young Iee Park, Noe Kyeong Kim, Chee Young Choe, Woo Ho Kim, Chul Woo Kim, Young Il Kim, Dae Seog Heo, Woo Hyun Chang; J Korean Cancer Assoc. 1992;24(5):656-665.

Treatment of advanced gastric cancer with 5-fluorouracil, etoposide and cisplatin(FEP): Joung Soon Jang, Young Hyuk Im, Sung Soo Yoon, Jae Yong Lee, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(5):702-707.

5-fluorouracil and low dose leucovorin in advanced colorectal carcinoma: Sung Soo Yoon, Young Hyuck Im, Jung Soon Jang, Jae Yong Lee, Chang In Suh, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(5):737-742.

Phase II study of 5-fluorouracil and recombinant interferon-gamma in patients with advanced colorectal cancer: Heung Tae Kim, Chang In Suh, Si Young Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1992;24(5):743-758.

Chemotherapy of Advanced Soft Tissue Sarcoma with Etoposide, Ifosfamide, and Cisplatin (VIP): Won Seog Kim, Kyung Hae Jung, Hyun Ah Kim, Sung Hyun Yang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1997;29(1):128-135.

Clinicopathologic Comparison of Intermediate or High Grade Peripheral T-Cell Lymphoma with Diffuse B-Cell Lymphoma: Kyung Hae Jung, In Sook Woo, Heung Moon Chang, Dae Seog Heo, Yung Jue Bang, Chul Woo Kim, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1997;29(1):136-145.

A Case of Solitary Bone Plasmacytoma of the Middle Cranial Fossa: Soo Mee Bang, Won Sup Lee, In Ho Kim, Dae Seog Heo, Yung Jue Bang, Dae Hee Han, Noe Kyeong Kim; J Korean Cancer Assoc. 1997;29(1):182-182.

IMVP-16/Pd (Ifosfamide/Methotrexate/VP-16/Prednisone) Combination Chemotherapy for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma: Ki Hyeong Lee, Young Iee Park, Heung Moon Chang, Tae You Kim, Keong Hae Jung, In Suk Woo, Young Hyuck Im, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1997;29(3):486-494.

Phase III Randomized Trial of ACNU in Addition to Surgery and Radiotherapy for Patients with Supratentorial Malignant Gliomas: Hee Won Jung, Chang Wan Oh, Chun Kee Chung, Hee Jin Yang, Kil Soo Choi, Dae Hee Han, Je G Chi, Yung Jue Bang, Dae Seog Heo, Noe Kyeong Kim, Yoon Ok Ahn, Il Han Kim; J Korean Cancer Assoc. 1997;29(4):608-615.

Restrospective Cohort Study of Survival and Prognostic Factors in Patients with Terminal Cancer: Young Ho Yun, Dae Seog Heo, Jong Myon Bae, Seock Ah Im, Tai Woo Yoo, Bong Yul Huh, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(1):188-197.

Peripheral T - cell Lymphomas Presenting as Fever of Unknown Origin: Dae Seog Heo, Keun Seok Lee, Joor Yung Huh, Yung Jue Bang, Seon Yang Park, Chul Woo Kim, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(2):329-337.

Restrospective Cohort Study of Survival and Prognostie Factors in Patients with Terminal Cancer: Young Ho Yun, Dae Seog Heo, Jong Myon Bae, Seock Ah Im, Tai Woo Yoo, Bong Yul Huh, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(2):384-393.

Prognostic Factor Analysis of Aggressive Non - Hodgkin's Lymphoma Based on International Prognostic Index Model: Min Hee Ryu, Young Iee Park, Hark Kyun Kim, Dae Ho Lee, Joo Young Jeong, Dong Wan Kim, Im Il Na, Ji Hyun Kim, Se Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seon Yang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1998;30(6):1269-1278.

Patterns of the First Failure after Curative Resection of Gastric Cancer in Korean Female Patients: Hark Kyun Kim, Min Hee Ryu, Soo Mi Bang, Keun Young Yoo, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(2):246-255.

A Phase 2 Study of VP-16 , Ifosfamide , and Cisplatin ( VIP ) Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Limited Small Cell Lung Cancer: Seok Ah Im, Moon Hee Lee, Chul Won Jung, Dae Seog Heo, Yung Jue Bang, Young Soo Shim, Chan Il Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(2):306-312.

Patterns of the Recurrence of Breast Cancer in Korean Female Patients: Hark Kyun Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(3):509-516.

Clinical Characteristics and Prognostic Factors of Metastatic Tumor of Unknown Primary: Eun Kyung Cho, Keun Seok Lee, Chul Won Jung, Won Seog Kim, Ki Hyeong Lee, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(3):607-616.

Clinicopathologic Charcteristics of Korean Non - Hodgkin's Lymphomas Based on REAL Classification: Yoon Koo Kang, Bong Seog Kim, Tae Won Kim, Mon Hee Ryu, Seung Sook Lee, Baek Yeol Ryoo, Tae You Kim, Young Hyuck Im, Kyoo Hyung Lee, Jooryung Huh, Dae Seog Heo, Yung Jue Bang, Chulwoo Kim, Jung Shin Lee, Byoung Kook Kim, Woo Kun Kim, Sang Hee Kim, Noe Kveong Kim; J Korean Cancer Assoc. 1999;31(4):641-652.

A Phase 2 Study with Vinorelbine and Ifosfamide in the Inoperable Non - small Cell Lung Cancer: Moon Hee Lee, Young Jin Yoo, Soo Mi Bang, Gyung Hae Joung, Hyo Jin Kim, Dong Bok Shin, Soon Nam Lee, Seong Rok Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(5):972-978.

The Effectiveness and Safety of DA-3030 ( rhG-CSF ) for Chemotherapy - induced Neutropenia: A Randomized Controlled Trial: Dae Ho Lee, Cheolwon Suh, Keunchil Park, Tae Won Kim, Jung Gyun Kim, Won Seog Kim, Won Ki Kang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(5):995-1002.

Role of PET Scan in Staging Work - up and Reevaluation after Therapy in Lymphoma: Young Jin Yuh, Chul Won Jung, Seock Ah Im, Dae Seog Heo, Yung Jue Bang, Seonyang Park, June Key Chung, Myung Chul Lee, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(5):1011-1017.

Antiemetic Effect of Granisetron plus Dexamethasone for the Patients Refractory to Metoclopramide , Dexamethasone and Lorazepam ( MDL ): Se Hoon Lee, Dong Wan Kim, Kyun Hae Jung, Soo Mee Bang, Jae Ho Byun, Heung Moon Chang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(5):1027-1034.

Phase II Multicenter Trial of Paclitaxel for Metastatic Breast Cancer: Jae Ho Byun, Sung Soo Yoon, Chan Hyung Park, Sung Rok Kim, Si Young Kim, Hyo Jin Kim, Soo Mee Bang, Heung Moon Chang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2000;32(3):545-552.

Prognostic Factors of Gastrointestinal Leiomyosarcoma in Korea: Se Hoon Lee, Hee Jeoung Cha, Jee Hyun Kim, Im Il Na, Jun Hee Lee, Hark Kyun Kim, Keun Seok Lee, Won Sup Lee, Chong Jai Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2000;32(6):1022-1030.

A Phase II Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in 5- Fluorouracil-Pretreated Metastatic Colorectal Cancer: Keun Seok Lee, Won Sup Lee, Hark Kyun Kim, Joo Young Jeong, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2001;33(2):99-105.

A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer: Won Sup Lee, Keun Seok Lee, Ki Hyun Kim, Baek Yeol Ryoo, Won Seog Kim, Won Ki Kang, Yoon Koo Kang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(3):225-228.

Discrepancies of the Values on the Withholding Futile Interventions between Physician and Family Members of Terminal Cancer Patients: Do Youn Oh, Mi Ra Kim, In Sil Choi, Yo Han Joh, Byung Su Kim, Do Yeun Kim, Jee Hyun Kim, Se Hoon Lee, Tae You Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(4):350-356.

Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer: Yo Han Joh, Tae You Kim, Im Il Na, Do Youn Oh, Byung Su Kim, Jee Hyun Kim, Do Yeun Kim, Se Hoon Lee, Chul Gyu Yoo, Choon Taek Lee, Young Whan Kim, Dae Seog Heo, Yung Jue Bang, Sung Koo Han, Young Soo Shim, Noe Kyeong Kim; Cancer Res Treat. 2001;33(5):373-376.

A Phase II Study of Genexol(R) (paclitaxel) in Metastatic Breast Cancer: Joo Young Jung, Hyun Chul Jeong, Sung Soo Yoon, Jae Hoon Lee, Jun Seok Kim, Hyo Jin Kim, Ki Hyun Kim, Jun O Park, Won Seop Lee, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(6):451-457.

Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer: Byung Su Kim, Do Youn Oh, Yo Han Joh, Do Yeun Kim, Jee Hyun Kim, Se Hoon Lee, Dae Ho Lee, Tae You Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(6):469-473.

A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer: Se Hoon Lee, Keunchil Park, Cheolwon Suh, Hoon Kyo Kim, Jun Suk Kim, Young Hyuck Im, Sang We Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2003;35(1):30-34.

Editorial Cancer Gene Therapy: Limitations and Progress: Dae Seog Heo; Cancer Res Treat. 2003;35(3):175-176.

Original Articles Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients: Jin-Soo Kim, Ji Yeon Baek, Sook Ryun Park, In Sil Choi, Sang-Il Kim, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2004;36(6):372-376.

Gemcitabine and Vinorelbine Combination Chemotherapy in Anthracycline- and Taxane-pretreated Advanced Breast Cancer: Hye Jin Kim, Jin-Soo Kim, Myung-Deok Seo, So-Yeon Oh, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang; Cancer Res Treat. 2008;40(2):81-86.

Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients: Joo Ho Lee, Hong-Gyun Wu, Hak Jae Kim, Dong-Wan Kim, Se-Hoon Lee, Tae Min Kim, Young Whan Kim, Dae Seog Heo; Cancer Res Treat. 2012;44(4):242-250.

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution: Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo; Cancer Res Treat. 2013;45(3):178-185.

Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer: Ji-Won Kim, Youngil Koh, Dong-Wan Kim, Yong-Oon Ahn, Tae Min Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang; Cancer Res Treat. 2013;45(4):325-333.